doi: 10.1016/j.neuropharm.2016.09.002 112 RodriguesMSFerreiraSGQuirozCEarleyCJGarca-BorregueroDCunhaRAet al
Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, (editors): Goldfrank's Toxicological Emergencies
Produced under carefully monitored manufacturing standards, this research formulation is supplied for qualified researchers conducting experimental work in professional laboratory environments
Evolution of Longer-Acting Formulations Once the chemistry was established, the next mission scientists faced was to make GLP-1 agonists last longer in the body, so patients wouldnt have to keep poking themselves like a pincushion
That shift is clinically meaningful because formulation barriers have been a major constraint on broader uptake
Beta-blockers, RAAS blockers, MRAs, and diuretics each target different aspects of the disease